Akebia Therapeutics, Inc. Forecast, price target & analysts
$1.78
4.05%
today
Nasdaq,
Nov 13, 09:17 pm CET
Akebia Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Powered by
Akebia Therapeutics, Inc. Classifications & Recommendation:
Buy
91%
Hold
9%
Akebia Therapeutics, Inc. Price Target
| Target Price | $7.14 |
| Price | $1.85 |
| Potential |
285.95%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Akebia Therapeutics, Inc. 2026 .
The average Akebia Therapeutics, Inc. target price is $7.14.
This is
285.95%
register free of charge
$10.50
467.57%
register free of charge
$6.06
227.57%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Akebia Therapeutics, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Akebia Therapeutics, Inc. stock has an average upside potential 2026 of
285.95%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 160.18 | 245.69 |
| 17.70% | 53.38% | |
| Net Margin | -43.33% | -0.27% |
| 62.40% | 99.38% |
7 Analysts have issued a sales forecast Akebia Therapeutics, Inc. 2025 . The average Akebia Therapeutics, Inc. sales estimate is
$246m
Unlock
20.60%
higher
Unlock
$275m
34.88%
Unlock
$213m
4.57%
Unlock
This results in the following potential growth metrics:
7 Akebia Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Akebia Therapeutics, Inc. net profit estimate is
$-670k
Unlock
98.16%
higher
Unlock
$47.0m
228.70%
Unlock
$-30.9m
15.21%
Unlock
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.33 | 0.00 |
| 17.86% | 100.00% | |
| P/E | negative | |
| EV/Sales | 2.20 |
Current Akebia Therapeutics, Inc. Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 30 2025 |
| BTIG |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 04 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 30 2025 |
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Apr 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 04 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 14 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
